Caris Life Sciences, Inc. - CAI EV/EBITDA Multiple

Caris Life Sciences (CAI) - corporate logo

Caris Life Sciences, Inc. (CAI) maintains a high reputation in precision oncology due to the accuracy of its tumor analysis. The business is protected by sophisticated laboratories and stringent regulatory standards. The company's EV/EBITDA ratio, accounting for debt load, filters out market noise, and its current level is 39.11. Scaling DNA testing reduces costs, ensuring steady growth of operating leverage and equipment payback.

CAI Caris Corp: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization in the range 11/23/2025 - 11/16/2026

Analytical breakdowns for Caris Life Sciences, Inc.

- market price and analyst price targets:
Comprehensive company analysis:CAI (carislifesciences.com)
Original product of carislifesciences.com

This multiple determines the total value of Caris Life Sciences, Inc. (CAI) by comparing market capitalization with debt and operating profit before taxes. The metric is sensitive to debt load, allowing investors to assess the real price of the business per unit of EBITDA. Analyzing the business valuation level via EV/EBITDA helps determine the extent to which the market discounts intellectual capital and the stability of the R&D staff. Low indicator values, while maintaining the loyalty of leading bioinformaticians, signal an undervaluation of the company's fundamental assets.